<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.2minutemedicine.com/feed/</title><link>https://www.2minutemedicine.com/feed/</link><description>Individual feed output.</description><lastBuildDate>Mon, 19 Jan 2026 07:21:10 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>2 Minute Medicine Rewind January 19, 2026</title><link>https://www.2minutemedicine.com/2-minute-medicine-rewind-january-19-2026/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2017/05/DVT2_cc_wiki_JamesHeilmanMD_edited-300x150.jpg</image_url><description>Electronic Intervention for Patient-Managed Benzodiazepine Tapering 1. An electronic intervention promoting self-management of benzodiazepine cessatio...</description><pubDate>Mon, 19 Jan 2026 11:00:51 GMT</pubDate></item><item><title>Ethosuximide may not be effective for the treatment of abdominal pain in irritable bowel syndrome</title><link>https://www.2minutemedicine.com/ethosuximide-may-not-be-effective-for-the-treatment-of-abdominal-pain-in-irritable-bowel-syndrome/</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture2.png</image_url><description>1. Ethosuximide was not superior to placebo for the treatment of abdominal pain in adults with irritable bowel syndrome. Evidence Rating Level: 1 (Exc...</description><pubDate>Sat, 17 Jan 2026 00:00:52 GMT</pubDate></item><item><title>Edaravone dexborneol improves functional independence in patients with acute ischaemic stroke following endovascular thrombectomy</title><link>https://www.2minutemedicine.com/edaravone-dexborneol-improves-functional-independence-in-patients-with-acute-ischaemic-stroke-following-endovascular-thrombectomy/</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture9.png</image_url><description>1. Compared to placebo, edaravone dexborneol improved functional independence at 90 days in patients with acute ischaemic stroke who underwent endovas...</description><pubDate>Fri, 16 Jan 2026 00:00:40 GMT</pubDate></item><item><title>Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients</title><link>https://www.2minutemedicine.com/yartemlea-narsoplimab-wuug-improves-platelets-hemolysis-organ-function-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-transplant-patients/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2014/12/Human_embryonic_stem_cells-300x150.png</image_url><description>1. Yartemlea (narsoplimab-wuug) is the first on‑label complement inhibitor for hematopoietic stem cell transplant (HSCT) associated thrombotic microan...</description><pubDate>Thu, 15 Jan 2026 18:48:46 GMT</pubDate></item><item><title>FDA highlights flexible chemistry manufacturing controls expectations for cell and gene therapies</title><link>https://www.2minutemedicine.com/fda-highlights-flexible-chemistry-manufacturing-controls-expectations-for-cell-and-gene-therapies/</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture10.png</image_url><description>1. New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, in...</description><pubDate>Thu, 15 Jan 2026 15:20:39 GMT</pubDate></item></channel></rss>